Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ et al. Lancet Oncol. 2016 Sep 16. pii: S1470-2045(16)30375-8. doi: 10.1016/S1470-2045(16)30375-8. [Epub ahead of print].
A selective histone deacetylase inhibitor for myeloma.
Pratt G et al. Lancet Oncol. 2016 Sep 16. pii: S1470-2045(16)30407-7. doi: 10.1016/S1470-2045(16)30407-7. [Epub ahead of print].
Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myelomaharboring the BRAF V600E mutation.
Mey UJ et al. Hematol Oncol. 2016 Sep 19. doi: 10.1002/hon.2353. [Epub ahead of print].
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.
Leng Y et al. Chin J Cancer. 2016 Sep 8;35(1):86. doi: 10.1186/s40880-016-0140-0.
Second generation proteasome inhibitors in multiple myeloma.
Gozzetti A et al. Anticancer Agents Med Chem. 2016 Sep 2. [Epub ahead of print].
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB et al. Cytotherapy. 2016 Aug 31. pii: S1465-3249(16)30467-4. doi: 10.1016/j.jcyt.2016.07.003. [Epub ahead of print].
Phase II Trial of Nab-paclitaxel in Patients with Relapsed or Refractory Multiple Myeloma.
Jain T et al. Am J Hematol. 2016 Sep 1. doi: 10.1002/ajh.24548. [Epub ahead of print].
Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma.
Iida S et al. Cancer Sci. 2016 Sep;107(9):1281-9. doi: 10.1111/cas.13000. Epub 2016 Sep 1.